Anti-integrin αvβ6 autoantibodies in patients with primary sclerosing cholangitis

1. Lazaridis KN, LaRusso NF. Primary sclerosing cholangitis.

N Engl J Med. 2016;375:1161–70.

2. Dyson JK, Beuers U, Jones DEJ, et al. Primary sclerosing

cholangitis. The Lancet. 2018;391:2547–59.

3. Vesterhus M, Karlsen TH. Emerging therapies in primary sclerosing cholangitis: pathophysiological basis and clinical opportunities. J Gastroenterol. 2020;55:588–614.

4. Bakhshi Z, Hilscher MB, Gores GJ, et al. An update on primary

sclerosing cholangitis epidemiology, outcomes and quantification

of alkaline phosphatase variability in a population-based cohort.

J Gastroenterol. 2020;55:523–32.

5. Isayama H, Tazuma S, Kokudo N, et al. Clinical guidelines for

primary sclerosing cholangitis 2017. J Gastroenterol.

2018;53:1006–34.

6. Karrar A, Broome U, Sodergren T, et al. Biliary epithelial cell

antibodies link adaptive and innate immune responses in primary

sclerosing cholangitis. Gastroenterology. 2007;132:1504–14.

7. Xu B, Broome U, Ericzon B-G, et al. High frequency of

autoantibodies in patients with primary sclerosing cholangitis that

bind biliary epithelial cells and induce expression of CD44 and

production of interleukin 6. Gut. 2002;51:120–7.

8. Kuwada T, Shiokawa M, Kodama Y, et al. Identification of an

anti-integrin alphavbeta6 autoantibody in patients with ulcerative

colitis. Gastroenterology. 2021;160(2383–94): e21.

9. Uzzan M, Martin JC, Mesin L, et al. Ulcerative colitis is characterized by a plasmablast-skewed humoral response associated

with disease activity. Nat Med. 2022;28:766–79.

10. Rydell N, Ekoff H, Hellstrom PM, et al. Measurement of serum

IgG anti-integrin alphavbeta6 autoantibodies is a promising tool

in the diagnosis of ulcerative colitis. J Clin Med. 2022;11:1881.

11. Hynes R. Integrins: versatility, modulation, and signaling in cell

adhesion. Cell. 1992;69:11–25.

12. Breuss JM, Gallo J, DeLisser HM, et al. Expression of the b6

integrin subunit in development, neoplasia and tissue repair

suggests a role in epithelial remodeling. J Cell Sci.

1995;108:2241–51.

13. Breuss JM, Gillett N, Lu L, et al. Restricted distribution of

integrin beta 6 mRNA in primate epithelial tissues. J Histochem

Cytochem. 1993;41:1521–7.

14. Guillot A, Guerri L, Feng D, et al. Bile acid-activated macrophages promote biliary epithelial cell proliferation through integrin alphavbeta6 upregulation following liver injury. J Clin

Invest. 2021;131:e132305.

15. Weil P, Rvd Bruck, Ziegenhals T, et al. b6 integrinosis: a new

lethal autosomal recessive ITGB6 disorder leading to impaired

conformational transitions of the aVb6 integrin receptor. Gut.

2020;69:1359–61.

16. Ludwig DR, Anderson MA, Itani M, et al. Secondary sclerosing

cholangitis: mimics of primary sclerosing cholangitis. Abdom

Radiol (NY). 2023;48:151–65.

17. Kornbluth A, Sachar DB, Practice Parameters Committee of the

American College of G. Ulcerative colitis practice guidelines in

adults: American college of gastroenterology practice parameters

committee. Am J Gastroenterol. 2010;105:501–23 (quiz 24).

J Gastroenterol (2023) 58:778–789

18. Maaser C, Sturm A, Vavricka SR, et al. ECCO-ESGAR guideline

for diagnostic assessment in IBD part 1: initial diagnosis, monitoring of known IBD, detection of complications. J Crohns

Colitis. 2019;13:144–64.

19. Loftus EV Jr, Harewood GC, Loftus CG, et al. PSC-IBD: a

unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut. 2005;54:91–6.

20. Boonstra K, van Erpecum KJ, van Nieuwkerk KM, et al. Primary

sclerosing cholangitis is associated with a distinct phenotype of

inflammatory

bowel

disease.

Inflamm

Bowel

Dis.

2012;18:2270–6.

21. Krugliak Cleveland N, Rubin DT, Hart J, et al. Patients with

ulcerative colitis and primary sclerosing cholangitis frequently

have subclinical inflammation in the proximal colon. Clin Gastroenterol Hepatol. 2018;16:68–74.

22. Palmela C, Peerani F, Castaneda D, et al. Inflammatory Bowel

disease and primary sclerosing cholangitis: a review of the phenotype and associated specific features. Gut Liver.

2018;12:17–29.

23. Gulamhusein AF, Eaton JE, Tabibian JH, et al. Duration of

inflammatory bowel disease is associated with increased risk of

cholangiocarcinoma in patients with primary sclerosing cholangitis and IBD. Am J Gastroenterol. 2016;111:705–11.

24. Weinreb PH, Simon KJ, Rayhorn P, et al. Function-blocking

integrin alphavbeta6 monoclonal antibodies: distinct ligand-

789

25.

26.

27.

28.

29.

mimetic and nonligand-mimetic classes. J Biol Chem.

2004;279:17875–87.

Zhang K, Chen J. The regulation of integrin function by divalent

cations. Cell Adh Migr. 2012;6:20–9.

Takagi J, Petre BM, Walz T, et al. Global conformational rearrangements in integrin extracellular domains in outside-in and

inside-out signaling. Cell. 2002;110:599–611.

Shiokawa M, Kodama Y, Sekiguchi K, et al. Laminin 511 is a

target antigen in autoimmune pancreatitis. Sci Transl Med.

2018;10:eaaq0997.

Ji SG, Juran BD, Mucha S, et al. Genome-wide association study

of primary sclerosing cholangitis identifies new risk loci and

quantifies the genetic relationship with inflammatory bowel disease. Nat Genet. 2017;49:269–73.

Parise LV, Helgerson SL, Steiner B, et al. Synthetic peptides

derived from fibrinogen and fibronectin change the conformation

of purified platelet glycoprotein IIb-IIIa. J Biol Chem.

1987;262:12597–602.

Publisher’s Note Springer Nature remains neutral with regard to

jurisdictional claims in published maps and institutional affiliations.

123

...